Il-22 Directly Regulates Intestinal Stem Cells, Protecting Epithelium from Gvhd and Reducing Gvhd Mortality
Caroline A. Lindemans,Anna Mertelsmann,Margaret O'Connor,Marco Calafiore,Jarrod A. Dudakov,Robert Jenq,Enrico Velardi,Lauren Young,Odette M. Smith,Gillian Lawrence,Natalie Luo,Juliet Ivanov,Guoqiang Hua,Laura Martin,Chen Liu,Richard Kolesnick,Marcel R. M. van den Brink,Alan M. Hanash
DOI: https://doi.org/10.1016/j.bbmt.2014.11.058
2015-01-01
Biology of Blood and Marrow Transplantation
Abstract:Little is known about regulation of the intestinal stem cell (ISC) compartment in gut GVHD. We have found that Interleukin-22 (IL-22) is important for ISC recovery after BMT. However, the mechanism and specific epithelial targets of IL-22 are poorly understood. Using clinically modeled LP into C57BL/6 (B6) minor antigen-mismatched BMT (H-2b into H-2b), we found that daily treatment with recombinant murine IL-22 (4ug IP starting D7 post-BMT) led to reduced GVHD pathology in small intestine (SI) and large intestine (LI) three weeks after transplant (p<0.001) without altering GVL or alloreactivity. Mice treated with IL-22 (no pharmacologic immunosuppression) maintained more Lgr5+ ISCs and demonstrated significantly greater ISC proliferation (p<0.01). Although IL-22 is thought to regulate Paneth cells (PCs), and PCs make up the SI stem cell niche, IL-22-mediated protection of ISCs was not due to niche augmentation, as PC numbers, PC-derived growth factors (EGF, Wnt3), and stroma-derived growth factors (R-spondin 3) were all unchanged after IL-22 administration. However, antimicrobial proteins Reg3β and Reg3γ were both upregulated in IL-22-treated mice (p<0.01), suggesting enhanced gut barrier function. To evaluate direct effects on epithelial regeneration, we performed intestinal organoid cultures in the presence of IL-22. Organoids generated from wild-type B6 crypts demonstrated substantially increased size after seven days of culture with IL-22 (SI p<0.001, Fig. 1; LI p<0.05). Co-culturing crypts with innate lymphoid cells, potent producers of IL-22 in vivo, also led to increased organoid size. IL-22 significantly increased organoid EdU incorporation and new crypt budding, and serial passaging with IL-22 greatly increased organoid expansion, suggesting that IL-22 could augment ISC regeneration. IL-22 receptor staining further indicated a direct effect of IL-22 on ISCs rather than the stem cell niche, as PCs were found to express very little IL-22 receptor (Fig. 2). Indeed, IL-22 led to expansion of the Lgr5+ ISC pool within SI organoids (Fig. 2), activated STAT3 phosphorylation in Lgr5+ cells, and increased size and budding of organoids cultured from purified SI ISCs (p<0.05). To investigate potential for clinical translation, we next tested a recombinant human IL-22 dimer/Fc fusion molecule (F-652, Generon Corp., Shanghai). F-652 significantly increased the size of SI and LI organoids (p<.05). Using the LP into B6 BMT model described above, we also found that treatment with F-652 (100 μg/kg subQ every other day starting D7 post-BMT) significantly improved both systemic GVHD scoring and survival (Fig. 3). In summary, we found that IL-22 can bridge immune function and tissue regeneration by acting directly on epithelial stem cells. IL-22 therapy may represent a novel approach to promote intestinal recovery in GVHD patients without increasing post-transplant immunodeficiency.Figure 2ISCs are expanded by IL-22 in vitro.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3In vivo administration of F-652 (rhlL-22) rescues mice from GVHD.View Large Image Figure ViewerDownload Hi-res image Download (PPT)